Targeted agent selumetinib shows promise in biliary cancer

The experimental agent selumetinib has shown promising results in people with advanced biliary cancer, a malignancy of the bile ducts and gall bladder, according to a multi-institutional clinical trial. Most patients are diagnosed at later stages of the disease, which has a universally poor outcome. The study provides a strong rationale for developing this agent further in larger trials, probably in combination with other drugs.

Read the whole article on Science Daily

More from Science Daily